CONCLUSION
The elucidation of complex mutation profiles through NGS signifies a
paradigm shift in oncological research. Unveiling the co-occurrence of
BRAF and HRAS mutations in RMS, especially the enigmatic Class III BRAF
mutation, holds the potential to redefine therapeutic strategies.
Targeting these unique mutations presents a remarkable opportunity for
innovative treatment modalities.